Bavachinin, a novel natural pan-PPAR agonist.

Bavachinin is a natural compound isolated from the seeds of Psoralea corylifolia L. and the Chinese herb Fructus Psoraleae with potent anti-angiogenic activity.

Product information

CAS Number: 19879-30-2

Molecular Weight: 338.40

Formula: C21H22O4

Synonym:

7-O-Methylbavachin

Bavachinin A

Chemical Name: (2S)-2-(4-hydroxyphenyl)-7-methoxy-6-(3-methylbut-2-en-1-yl)-3, 4-dihydro-2H-1-benzopyran-4-one

Smiles: CC(C)=CCC1=CC2C(=O)C[C@H](OC=2C=C1OC)C1C=CC(O)=CC=1

InChiKey: VOCGSQHKPZSIKB-FQEVSTJZSA-N

InChi: InChI=1S/C21H22O4/c1-13(2)4-5-15-10-17-18(23)11-20(14-6-8-16(22)9-7-14)25-21(17)12-19(15)24-3/h4,6-10,12,20,22H,5,11H2,1-3H3/t20-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 125 mg/mL (369.39 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Bavachinin inhibits increases in HIF-1α activity in human KB carcinoma (HeLa cellderivative)and human HOS osteosarcoma cells under hypoxia in a concentration-dependent manner, probably by enhancing the interaction between von Hippel-Lindau (VHL) and HIF-1α. Furthermore, Bavachinin decreases transcription of genes associated with angiogenesis and energy metabolism that are regulated by HIF-1, such as vascular endothelial growth factors (VEGF), Glut1 and Hexokinase2. Bavachinin also inhibits tube formation in human umbilical vein endothelial cells (HUVECs) as well as in vitro migration of KB cells. Bavachinin inhibits nitricoxide production in macrophages activated by lipopolysaccharide[2].

In Vivo:

In db/db and DIO mice, BVC treatment ameliorates diabetes, hyperlipidaemia and BVC improves hepatotoxicity. BVC enhances glucose transport and utilisation, hepatic lipid turnover and fatty acid metabolism through PPAR networks, thereby improving insulin sensitivity, dyslipidaemia and fatty liver[1]. In vivo studies show that injecting Bavachinin thrice weekly for four weeks significantly reduces tumor volume and CD31 expression in nude mice with KB xenografts[2]. Following IV administration of bavachinin at 25 mg/kg to naïve female BALB/c mice, clearance is high (mean CL = 299.72 mL/min/kg) and is approximately 3.33-fold of hepatic blood flow. The mean volume of distribution of bavachinin is 11881.67 mL/kg, it is 16.39 times of total body water volume (725 mL/kg), indicating high extravascular distribution. The mean terminal half-life following IV dosing is 0.70 h, this is reflected a tight correlation between the clearance and terminal half-life. The PK properties of bavachinin are characterized as rapid oral absorption, high clearance, and poor absolute bioavailability following single oral and intravenous administration to naïve female BALB/c mice[3].

References:

1. Feng L, et al. Diabetologia. 2016, 59(6):1276-86.
2. Nepal M, et al. Eur J Pharmacol. 2012, 691(1-3):28-37.
3. Liu L, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2
4. Liu L, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2

Products are for research use only. Not for human use.